Ezetimibe (DrugBank: Ezetimibe)
4 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 1 |
| 79 | 家族性高コレステロール血症（ホモ接合体） | 6 |
| 93 | 原発性胆汁性胆管炎［原発性胆汁性肝硬変 (~2017.3)］ | 1 |
| 260 | シトステロール血症 | 11 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02548936 (ClinicalTrials.gov) | April 2015 | 31/8/2015 | Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE | Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy in Reduction of Progression of Atherosclerosis Among Patients With Systemic Lupus Erythematosus: A Randomized Single-Blind Trial | Atherosclerosis | Drug: Ezetimibe+Simvastatin Drug Combination | Peking Union Medical College Hospital | NULL | Enrolling by invitation | 18 Years | 65 Years | Both | 30 | Phase 0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03933293 (ClinicalTrials.gov) | May 13, 2019 | 28/4/2019 | A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH | A Phase 2 Study to Evaluate the Safety and Efficacy of PCSK9 Inhibitor AK102 in Patients With Homozygous Familial Hypercholesterolemia (HoFH) | Homozygous Familial Hypercholesterolemia | Drug: AK102;Drug: Statins;Drug: Ezetimibe | Akeso | AD Pharmaceuticals Co., Ltd. (Guangzhou) | Recruiting | 18 Years | N/A | All | 59 | Phase 2 | China |
| 2 | NCT03510715 (ClinicalTrials.gov) | August 31, 2018 | 18/4/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia | Hypercholesterolemia | Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: Lovastatin | Sanofi | Regeneron Pharmaceuticals | Completed | 8 Years | 17 Years | All | 18 | Phase 3 | Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States |
| 3 | NCT00704535 (ClinicalTrials.gov) | March 2006 | 23/6/2008 | Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED) | Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Ezetimibe Among Filipino Patients | Primary Hypercholesterolemia;Homozygous Familial Hypercholesterolemia | Drug: Ezetimibe | Merck Sharp & Dohme Corp. | NULL | Completed | 18 Years | N/A | All | 4105 | N/A | Philippines |
| 4 | NCT00092833 (ClinicalTrials.gov) | July 2002 | 23/9/2004 | Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) | An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia | Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors | Drug: Comparator: ezetimibe | Merck Sharp & Dohme Corp. | NULL | Terminated | 8 Years | N/A | All | 49 | Phase 3 | United States |
| 5 | NCT03885921 (ClinicalTrials.gov) | October 25, 2000 | 20/3/2019 | Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019) | Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial Hypercholesterolemia | Hypercholesterolemia | Drug: Ezetimibe;Drug: Atorvastatin;Drug: Simvastatin | Merck Sharp & Dohme Corp. | NULL | Completed | 12 Years | N/A | All | 44 | Phase 3 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03884452 (ClinicalTrials.gov) | May 3, 2000 | 6/3/2019 | Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018) | A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial Hypercholesterolemia | Familial Hypercholesterolemia | Drug: Atorvastatin;Drug: Simvastatin;Drug: Ezetimibe;Drug: Placebo for Ezetimibe | Merck Sharp & Dohme Corp. | NULL | Completed | 12 Years | N/A | All | 50 | Phase 3 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-006742-34-GB (EUCTR) | 20/12/2007 | 03/06/2007 | The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis. | The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis. | primary biliary cirrhosis MedDRA version: 9.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis | Barts and The London NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 70 | Phase 4 | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01584206 (ClinicalTrials.gov) | April 2012 | 16/4/2012 | Sitosterolemia Metabolism | Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe | Sitosterolemia | Drug: Ezetimibe | University of Manitoba | NULL | Completed | 16 Years | 99 Years | All | 8 | N/A | Canada |
| 2 | NCT00704444 (ClinicalTrials.gov) | June 2007 | 23/6/2008 | A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244) | Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy | Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia | Drug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s) | Merck Sharp & Dohme Corp. | Bayer | Completed | N/A | N/A | Both | 11332 | N/A | NULL |
| 3 | NCT00705211 (ClinicalTrials.gov) | June 2007 | 23/6/2008 | A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245) | Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy | Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia | Drug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s) | Merck Sharp & Dohme Corp. | Bayer | Completed | N/A | N/A | Both | 1794 | N/A | NULL |
| 4 | EUCTR2004-001580-22-DE (EUCTR) | 21/12/2004 | 20/10/2004 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | Homozygous Sitosterolemia | Trade Name: Ezetrol Product Name: Ezetrol Product Code: MK-0653 | MSD SHARP & DOHME GMBH | NULL | Not Recruiting | Female: yes Male: yes | 30 | Germany;United Kingdom | |||
| 5 | EUCTR2004-001580-22-GB (EUCTR) | 16/12/2004 | 24/02/2005 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | Homozygous Sitosterolemia | Trade Name: Ezetrol Product Name: Ezetrol Product Code: MK-0653 | Merck Sharp & Dohme Ltd | NULL | Not Recruiting | Female: yes Male: yes | 30 | Germany;United Kingdom | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00099996 (ClinicalTrials.gov) | December 2004 | 21/12/2004 | Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia | A Study to Assess Adding Ezetimibe 30 mg to Ongoing Treatment With Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia | Heart Diseases;Metabolism, Inborn Errors | Drug: SCH-58235;Drug: Ezetimibe | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | N/A | N/A | Both | 3 | Phase 3 | United States |
| 7 | NCT00092898 (ClinicalTrials.gov) | October 2004 | 23/9/2004 | An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous Sitosterolemia | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Merck Sharp & Dohme Corp. | NULL | Completed | 18 Years | 85 Years | All | 30 | Phase 3 | United States |
| 8 | NCT00092833 (ClinicalTrials.gov) | July 2002 | 23/9/2004 | Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) | An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia | Hypercholesterolemia, Familial;Lipid Metabolism, Inborn Errors | Drug: Comparator: ezetimibe | Merck Sharp & Dohme Corp. | NULL | Terminated | 8 Years | N/A | All | 49 | Phase 3 | United States |
| 9 | NCT00045812 (ClinicalTrials.gov) | March 2001 | 10/9/2002 | SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous Sitosterolemia | Lipoidosis | Drug: SCH-58235 | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | N/A | N/A | Both | 5 | Phase 2 | United States |
| 10 | NCT00092807 (ClinicalTrials.gov) | February 12, 2001 | 23/9/2004 | Sitosterolemia Extension Study (0653-003)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Merck Sharp & Dohme Corp. | NULL | Completed | 10 Years | N/A | All | 37 | Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT00092820 (ClinicalTrials.gov) | February 12, 2001 | 23/9/2004 | Sitosterolemia Extension Study (0653-004)(COMPLETED) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia | Lipid Metabolism, Inborn Errors;Heart Disease | Drug: MK0653, ezetimibe;Drug: Comparator: placebo | Merck Sharp & Dohme Corp. | NULL | Completed | 10 Years | N/A | All | 58 | Phase 3 | NULL |